Tumor microenvironment complexity and therapeutic implications at a glance

Abstract

The dynamic interactions of cancer cells with their microenvironment consisting of stromal cells (cellular part) and extracellular matrix (ECM) components (non-cellular) is essential to stimulate the heterogeneity of cancer cell, clonal evolution and to increase the multidrug resistance ending in cancer cell progression and metastasis. The reciprocal cell-cell/ECM interaction and tumor cell hijacking of non-malignant cells force stromal cells to lose their function and acquire new phenotypes that promote development and invasion of tumor cells. Understanding the underlying cellular and molecular mechanisms governing these interactions can be used as a novel strategy to indirectly disrupt cancer cell interplay and contribute to the development of efficient and safe therapeutic strategies to fight cancer. Furthermore, the tumor-derived circulating materials can also be used as cancer diagnostic tools to precisely predict and monitor the outcome of therapy. This review evaluates such potentials in various advanced cancer models, with a focus on 3D systems as well as lab-on-chip devices.

References 233

1. 1.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

2. 2.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

3. 3.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

4. 4.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

5. 5.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

6. 6.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

7. 7.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

8. 8.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

9. 9.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

16. 16.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

20. 20.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

23. 23.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

24. 24.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

25. 25.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

26. 26.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

28. 28.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

29. 29.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

30. 30.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

31. 31.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

32. 32.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

33. 33.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

34. 34.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

35. 35.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

36. 36.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

37. 37.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

38. 38.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

39. 39.
    Interaction of tumor cells with the microenvironment · 2011

    No notice
40. 40.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

41. 41.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

42. 42.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

43. 43.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

44. 44.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

45. 45.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

46. 46.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

47. 47.
    Eph/Ephrin Profiling in Human Breast Cancer Reveals Significant Associations between Expression Level and Clinical Outcome · 2011

    No notice
48. 48.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

49. 49.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

50. 50.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

51. 51.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

52. 52.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

53. 53.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

54. 54.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

55. 55.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

56. 56.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

57. 57.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

58. 58.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

59. 59.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

60. 60.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

61. 61.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

62. 62.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

63. 63.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

64. 64.
    Collagen reorganization at the tumor-stromal interface facilitates local invasion · 2006

    No notice
65. 65.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

66. 66.
    A Distinct Macrophage Population Mediates Metastatic Breast Cancer Cell Extravasation, Establishment and Growth · 2009

    No notice
67. 67.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

68. 68.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

69. 69.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

70. 70.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

71. 71.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

72. 72.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

73. 73.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

74. 74.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

75. 75.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

76. 76.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

77. 77.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

78. 78.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

79. 79.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

80. 80.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

81. 81.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

82. 82.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

83. 83.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

84. 84.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

85. 85.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

86. 86.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

87. 87.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

88. 88.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

89. 89.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

90. 90.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

91. 91.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

92. 92.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

93. 93.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

94. 94.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

95. 95.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

96. 96.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

97. 97.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

98. 98.
    Origins, structures, and functions of circulating DNA in oncology · 2016

    No notice
99. 99.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

100. 100.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

101. 101.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

102. 102.
     Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer · 2016

     No notice
103. 103.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

104. 104.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

105. 105.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

106. 106.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

107. 107.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

108. 108.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

109. 109.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

110. 110.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

111. 111.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

112. 112.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

113. 113.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

114. 114.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

115. 115.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

116. 116.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

117. 117.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

118. 118.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

119. 119.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

120. 120.
     Exosomes maintain cellular homeostasis by excreting harmful DNA from cells · 2017

     Corrected
121. 121.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

122. 122.
     Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration · 2017

     No notice
123. 123.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

124. 124.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

125. 125.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

126. 126.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

127. 127.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

128. 128.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

129. 129.
     Antibiotic-induced release of small extracellular vesicles (exosomes) with surface-associated DNA · 2017

     No notice
130. 130.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

131. 131.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

132. 132.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

133. 133.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

134. 134.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

135. 135.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

136. 136.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

137. 137.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

138. 138.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

139. 139.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

140. 140.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

141. 141.
     Cell death-based treatment of lung adenocarcinoma · 2018

     No notice
142. 142.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

143. 143.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

144. 144.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

145. 145.
     Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses · 2018

     No notice
146. 146.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

147. 147.
     Macrophage Clearance of Apoptotic Cells: A Critical Assessment · 2018

     No notice
148. 148.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

149. 149.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

150. 150.
     Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors · 2018

     No notice
151. 151.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

152. 152.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

153. 153.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

154. 154.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

155. 155.
     Apoptotic Cell-Derived Extracellular Vesicles: More Than Just Debris · 2018

     No notice
156. 156.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

157. 157.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

158. 158.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

159. 159.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

160. 160.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

161. 161.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

162. 162.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

163. 163.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

164. 164.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

165. 165.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

166. 166.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

167. 167.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

168. 168.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

169. 169.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

170. 170.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

171. 171.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

172. 172.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

173. 173.
     Role of Extracellular Matrix in Development and Cancer Progression · 2018

     No notice
174. 174.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

175. 175.
     The Role of the Extracellular Matrix and Its Molecular and Cellular Regulators in Cancer Cell Plasticity · 2018

     No notice
176. 176.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

177. 177.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

178. 178.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

179. 179.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

180. 180.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

181. 181.
     Apoptosis and apoptotic body: disease message and therapeutic target potentials · 2019

     No notice
182. 182.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

183. 183.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

184. 184.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

185. 185.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

186. 186.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

187. 187.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

188. 188.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

189. 189.
     Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1+ TAMs · 2019

     No notice
190. 190.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

191. 191.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

192. 192.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

193. 193.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

194. 194.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

195. 195.
     Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer · 2019

     No notice
196. 196.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

197. 197.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

198. 198.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

199. 199.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

200. 200.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

201. 201.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

202. 202.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

203. 203.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

204. 204.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

205. 205.
     The Ligands for Human IgG and Their Effector Functions · 2019

     No notice
206. 206.
     Cancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment · 2019

     No notice
207. 207.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

208. 208.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

209. 209.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

210. 210.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

211. 211.
     Emerging roles and therapeutic value of exosomes in cancer metastasis · 2019

     No notice
212. 212.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

213. 213.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

214. 214.
     Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis · 2019

     No notice
215. 215.
     Ontogeny of Tumor-Associated Macrophages · 2019

     No notice
216. 216.
     Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications · 2019

     No notice
217. 217.
     The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment · 2019

     No notice
218. 218.
     Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy · 2019

     No notice
219. 219.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

220. 220.
     The role of collagen in cancer: from bench to bedside · 2019

     No notice
221. 221.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

222. 222.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

223. 223.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

224. 224.
     Tumor-associated macrophages: an accomplice in solid tumor progression · 2019

     No notice
225. 225.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

226. 226.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

227. 227.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

228. 228.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

229. 229.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

230. 230.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

231. 231.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

232. 232.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

233. 233.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

Cited by papers we hold 30

• Molecular “Yin-Yang” Machinery of Synthesis of the Second and Third Fullerene C₆₀ Derivatives · 2025
  Not checked
• Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches · 2025
  No notice
• Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer · 2025
  No notice
• Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer · 2024
  No notice
• Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance · 2023
  No notice
• Reconstruction of the tumor spatial microenvironment along the malignant-boundary-nonmalignant axis · 2023
  No notice
• Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T · 2023
  No notice
• Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies · 2023
  No notice
• Single‐cell and spatial transcriptomics reveal POSTN + cancer‐associated fibroblasts correlated with immune suppression and tumour progression in non‐small cell lung cancer · 2023
  No notice
• Smart nanoparticles for cancer therapy · 2023
  No notice
• Tumor microenvironment in glioblastoma: Current and emerging concepts · 2023
  No notice
• A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy · 2023
  No notice
• Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment · 2022
  No notice
• FAK in Cancer: From Mechanisms to Therapeutic Strategies · 2022
  No notice
• Challenges and Opportunities for Immunoprofiling Using a Spatial High-Plex Technology: The NanoString GeoMx® Digital Spatial Profiler · 2022
  No notice
• Tumor microenvironment: barrier or opportunity towards effective cancer therapy · 2022
  No notice
• Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis · 2022
  No notice
• Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options · 2022
  No notice
• Managing the TME to improve the efficacy of cancer therapy · 2022
  No notice
• Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis · 2021
  No notice

and 10 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.